We came across a bullish thesis on C4 Therapeutics, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on CCCC. C4 Therapeutics, Inc.'s share was trading at $1.9600 as of January 29th. Copyright: dolgachov / 123RF Stock Photo C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins, stands at the forefront of targeted protein degradation (TPD), a next-generation approach in precision ...